Kamel Mabrouk is a prominent inventor based in Marseilles, France. He has made significant contributions to the field of toxin research, particularly in the development of novel derivatives that have therapeutic potential. With a total of 5 patents, his work focuses on addressing pathologies associated with calcium channel dysfunction.

Latest Patents

Mabrouk's latest patents include Maurotoxin, PI1, and HSTX1 derivatives. These derivatives of Maurotoxin (MTX) feature a disrupted native disulfide bridge pattern, which enhances their utility in treating conditions related to the dysfunction and activation of Ca-activated and voltage-gated K-channel subtypes, such as IKCa1 or Kv1.2. Notably, some derivatives involve substitutions of amino acid residues, resulting in a modified disulfide bridge pattern. Additionally, Maurocalcine and its analogues have been identified for their potential therapeutic uses, particularly in modifying the gating behavior of type 1 ryanodine receptors and as candidate immuno-suppressive drugs.

Career Highlights

Throughout his career, Kamel Mabrouk has worked with various companies, including Cellpep Pharma Inc. and Armel S.A. His innovative research has positioned him as a key figure in the field of toxin-based therapeutics.

Collaborations

Mabrouk has collaborated with notable professionals in his field, including Herve Rochat and Jean-Marc Sabatier. These collaborations have further enriched his research and development efforts.

Conclusion

Kamel Mabrouk's contributions to toxin research and his innovative patents highlight his role as a leading inventor in the field. His work continues to pave the way for new therapeutic approaches to calcium channel-related pathologies.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com